About IXINITY
IXINITY is a Healthcare company based in Chicago (United States) founded in 2012, and was acquired by Medexus Pharmaceuticals in November 2020. Information on hemophilia B treatment drug is provided by IXINITY. Its chief executive, as recorded, is Ken Dtremont. Its focus areas include Pharmaceutical Product Websites. Its legal entity is Medexus Pharma, Inc.
Company details
Founded in 2012 in Chicago, United States, IXINITY operates within the healthcare sector. Focus is directed toward hemophilia B, with information about the IXINITY drug disseminated via its domain, ixinity.com. Services encompass details on treatment applications and related medical insights. Leadership is held by CEO Ken Dtremont, and activities are based in the United States to support patient and professional resources.
- Headquarters Chicago, United States
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website ixinity.com
- Social LinkedIn Facebook
- Acquired by Medexus Pharmaceuticals (Nov 2020)
- Legal Name Medexus Pharma, Inc
- Investors
- Acquired byMedexus Pharmaceuticals
(Nov 2020)
Investors in IXINITY
IXINITY has secured backing from 1 investor. Prominent investors backing the company include Medexus Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical drugs are manufactured for rheumatology, immunology, and oncology sectors. | 2004 | medexus.com | Montreal, Canada |
Investor details for IXINITY
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of IXINITY
1 people are tracked at IXINITY (1 in leadership).
| Name | Role | Group |
|---|---|---|
Ken Dtremont | CEO | Leadership |
Complete people profiles for IXINITY
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of IXINITY
2 dated milestones of IXINITY across 8 years, from founding to its latest funding, stage changes and deals.
- Founded IXINITY is founded.
- Exit Acquired by Medexus Pharmaceuticals.
Top companies in Pharmacy & Healthcare Retail Systems
3 companies that operate in the same segment as IXINITY (Pharmacy & Healthcare Retail Systems) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Alto Pharmacy is focused on providing convenient prescription delivery services. | 2015 | San Francisco, California, United States | USD 591.64 M | 802 | ||
Optum is recognized as a leading health solution and care delivery organization. | 2011 | Eden Prairie, Minnesota, United States | USD 250 K | USD 383.36 M | 140 | |
Materials management and business analytics solutions for healthcare are provided. | 1992 | Mountain View, California, United States | USD 20 M | USD 1.18 B | 3,670 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about IXINITY
IXINITY was founded in 2012.
IXINITY is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Ken Dtremont is the CEO of IXINITY, as recorded in our data.
Founded in 2012 in Chicago, United States, IXINITY operates within the healthcare sector. Focus is directed toward hemophilia B, with information about the IXINITY drug disseminated via its domain, ixinity.com. Services encompass details on treatment applications and related medical insights. Leadership is held by CEO Ken Dtremont, and activities are based in the United States to support patient and professional resources.
IXINITY has 1 investor. Key investors include Medexus Pharmaceuticals.
IXINITY operates through Medexus Pharma, Inc.
Yes. IXINITY was acquired by Medexus Pharmaceuticals in November 2020.